"New guidelines from AANA for anesthesia care of patients using GLP-1 agonists like Ozempic and Saxenda, including fasting and additional screenings to mitigate
New research suggests that people who stop taking GLP-1 drugs for weight management can still maintain their weight loss following treatment by adhering to a regular exercise regime.
FDA approves Eli Lilly's Zepbound, a weekly injection for chronic weight management, for obese or overweight adults with at least one weight-related condition.
In the last three months of 2022, physicians prescribed more than 9 million doses of obesity drug Saxenda and two diabetes medications, Ozempic and Mounjaro.